Composite patient-reported outcomes and risk prediction for overall survival in advanced non-small cell lung cancer with first-line cemiplimab
In patients with advanced NSCLC receiving first-line cemiplimab-based therapy, composite PROs consisting of one functioning and one symptom scale had greater prognostic value than single PRO scales. Further development and analysis of composite PROs for clinical trials is warranted.
Authors
- Mahmut Gumus (ORCID: https://orcid.org/0000-0002-4323-0215)
- J. Harnett
- Eric Yan (ORCID: https://orcid.org/0000-0001-7390-0403)
- Miranda Gogishvili (ORCID: https://orcid.org/0000-0002-5143-6379)
- Ahmet Sezer
- David Gandara
- Tamta Makharadze
- Ruben G. W. Quek
Institutions
- Regeneron (United States) (US)
- Başkent University (TR)
- Highland Hospital (US)
- Global College (CY)
- Sylvester Comprehensive Cancer Center (US)
- Medical Technologies (Czechia) (CZ)
- Istanbul Medeniyet University (TR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-25
- DOI
- https://doi.org/10.3389/fonc.2026.1676687
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Regeneron Pharmaceuticals